Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]
- Elizabeth R. Plimack
- , Thomas Powles
- , Viktor Stus
- , Rustem Gafanov
- , Dmitry Nosov
- , Tom Waddell
- , Boris Alekseev
- , Frédéric Pouliot
- , Bohuslav Melichar
- , Denis Soulières
- , Delphine Borchiellini
- , Raymond S. McDermott
- , Ihor Vynnychenko
- , Yen Hwa Chang
- , Satoshi Tamada
- , Michael B. Atkins
- , Chenxiang Li
- , Rodolfo Perini
- , L. Rhoda Molife
- , Jens Bedke
- Royal Free London NHS Foundation Trust
- Queen Mary University of London
- Zaporizhia Medical Academy of Post-Gradate Education Ministry of Health of Ukraine
- Russian Ministry of Health
- Central Clinical Hospital With Outpatient Clinic
- The Christie NHS Foundation Trust
- Université Laval
- Palacký University Olomouc
- Centre Hospitalier de l’Université de Montréal Research Center
- Université Côte d'Azur
- University College Dublin
- Sumy State University
- Veterans General Hospital-Taipei
- Bell Land General Hospital
- Georgetown University
- Merck & Co.
- MSD UK
- University of Tübingen
- Vanderbilt University
Research output: Contribution to journal › Comment/debate
2
Scopus
citations